Entrada Therapeutics, Inc.
TRDA
$7.46
$0.010.13%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -7.67% | -1.41% | 11.26% | -2.39% | -148.45% |
| Total Depreciation and Amortization | 4.47% | -9.14% | -27.97% | 18.96% | 9.30% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 12.01% | 12.64% | -14.90% | 7.10% | 9.02% |
| Change in Net Operating Assets | 168.19% | -396.98% | -76.99% | 20.26% | 132.85% |
| Cash from Operations | 22.14% | -29.48% | -13.74% | 3.99% | 23.42% |
| Capital Expenditure | 75.00% | -121.26% | 21.05% | 162.18% | 75.96% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 103.32% | -6.51% | -40.92% | 43.63% | 474.86% |
| Cash from Investing | 103.61% | -7.32% | -40.71% | 45.31% | 606.61% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 250.00% | -47.92% | 2,300.00% | -97.63% | -3.71% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 250.00% | -47.92% | 2,300.00% | -97.63% | -3.71% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 256.33% | -405.12% | -113.90% | 347.88% | 113.92% |